Description:
Incyte Corporation (INCY), headquartered in Wilmington, Delaware, is a prominent biopharmaceutical company dedicated to developing innovative therapies for oncology and other serious medical conditions. Since its inception in 1991, Incyte has achieved significant commercial success with its leading product, Jakafi, which treats myelofibrosis and polycythemia vera, while also advancing a robust pipeline of drug candidates targeting various malignancies. The company's commitment to precision medicine, coupled with strategic collaborations, positions it at the forefront of addressing critical unmet medical needs in the healthcare sector. Through its emphasis on scientific innovation and improved patient outcomes, Incyte is poised to maintain its influential role in the biopharmaceutical landscape.
Address:
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, UNITED STATES, 19803
Fiscal year end:
December
Market capitalization:
$20.4 Billion
Dividend per share:
$0.00
How much was you spent on shares:
$1,000
How much will you earn in
10 years:
-20%
How much will you get:
$795
Prices dates:
30-10-2015: $117.53 and 31-10-2025: $93.48